Trial Profile
A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2019
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Triciribine (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Prescient Therapeutics
- 04 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 04 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 12 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.